Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCR-PDL1 in advanced solid tumors
NCT06504368Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DCR-PDL1 in solid tumor and non-Hodgkin lymphoma (NHL), sponsored by Novo Nordisk. Primary endpoints: Adverse Events at 8 weeks, Dose-Limiting Toxicities at 8 weeks and 45 more. Started May 2024; status: recruiting.
02
Drugs
DCR-PDL1
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06504368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504368.